Literature DB >> 9322848

Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats.

L Belayev1, R Busto, W Zhao, J A Clemens, M D Ginsberg.   

Abstract

The authors examined the effect of delayed high-concentration albumin therapy on ischemic injury in a highly reproducible model of middle cerebral artery (MCA) occlusion in rats. Male Sprague-Dawley rats weighing 270 to 320 g were anesthetized with halothane and subjected to 120 minutes of temporary MCA occlusion induced by means of a poly-L-lysine-coated intraluminal nylon suture inserted retrograde via the external carotid artery into the internal carotid artery and MCA. The agent (20% human serum albumin [HSA]) or control solution (sodium chloride 0.9%) was administered intravenously at a dosage of 1% of body weight immediately after suture removal following a 2-hour period of MCA occlusion. The animals' neurological status was evaluated during MCA occlusion (at 60 minutes) and daily for 3 days thereafter. The brains were perfusion-fixed, and infarct volumes and brain edema were determined. The HSA significantly improved the neurological score compared with saline at 24 hours after MCA occlusion. The rats treated with HSA also had significantly reduced total infarct volume (by 34%) and brain edema (by 81%) compared with saline-treated rats. There was a strong correlation between hematocrit level and brain edema (p < 0.01), and between total infarct volume or brain edema and neurological score at 24, 48, and 72 hours postinjury (p < 0.0002). These results strongly support the beneficial effect of delayed albumin therapy in transient focal ischemia and indicate its possible usefulness in treating patients with acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322848     DOI: 10.3171/jns.1997.87.4.0595

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  34 in total

1.  Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.

Authors:  Jose I Suarez; Renee H Martin
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

2.  Polynitroxyl albumin and albumin therapy after pediatric asphyxial cardiac arrest: effects on cerebral blood flow and neurologic outcome.

Authors:  Mioara D Manole; Patrick M Kochanek; Lesley M Foley; T Kevin Hitchens; Hülya Bayır; Henry Alexander; Robert Garman; Li Ma; Carleton J C Hsia; Chien Ho; Robert S B Clark
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-30       Impact factor: 6.200

Review 3.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 4.  Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Authors:  Jialing Liu; Yongting Wang; Yosuke Akamatsu; Chih Cheng Lee; R Anne Stetler; Michael T Lawton; Guo-Yuan Yang
Journal:  Prog Neurobiol       Date:  2013-11-27       Impact factor: 11.685

Review 5.  A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.

Authors:  Ligen Shi; Marcelo Rocha; Rehana K Leak; Jingyan Zhao; Tarun N Bhatia; Hongfeng Mu; Zhishuo Wei; Fang Yu; Susan L Weiner; Feifei Ma; Tudor G Jovin; Jun Chen
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-07       Impact factor: 6.200

6.  The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes.

Authors:  Jose I Suarez; Renee H Martin; Eusebia Calvillo; Catherine Dillon; Eric M Bershad; R Loch Macdonald; John Wong; Robert Harbaugh
Journal:  Stroke       Date:  2012-01-19       Impact factor: 7.914

7.  High dose human serum albumin for the treatment of acute ischemic stroke: a safety study.

Authors:  Sebastian Koch; Mauricio Concha; Tarek Wazzan; Jose G Romano; Alejandro Forteza
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

8.  Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?

Authors:  Rakesh Khatri; Mohammad Rauf Afzal; Gustavo J Rodriguez; Alberto Maud; Muhammad Shah Miran; Mohtashim Arbaab Qureshi; Salvador Cruz-Flores; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

9.  Activation and reversal of lipotoxicity in PC12 and rat cortical cells following exposure to palmitic acid.

Authors:  Frankis G Almaguel; Jo-Wen Liu; Fabio J Pacheco; Carlos A Casiano; Marino De Leon
Journal:  J Neurosci Res       Date:  2009-04       Impact factor: 4.164

Review 10.  Anemia and red blood cell transfusion in neurocritical care.

Authors:  Andreas H Kramer; David A Zygun
Journal:  Crit Care       Date:  2009-06-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.